BEIJING – Shenzhen-listed Chinese firm Nanjing Hicin Pharmaceutical Co. Ltd. has in-licensed an isocitrate dehydrogenase (IDH) inhibitor known as I111b from Italian oncology specialist Nerviano Medical Sciences Srl (NMS) to develop and commercialize the drug globally for patients with acute myeloid leukemia (AML).

Aveo Oncology Inc. and Kyowa Kirin Co. Ltd. amended their 2006 license agreement so that Kyowa Kirin can buy back the non-oncology rights of tivozanib in Aveo territories, including the U.S. and the EU, while Aveo retains U.S. rights in cancer.

LONDON – It's the technology that keeps on giving, and the Heptares unit of Sosei Group Corp. has attracted a further partner to its G protein-coupled receptor (GPCR) platform, signing up Takeda Pharmaceutical Ltd., in a deal worth up to $1.2 billion.